- Home
- Publications
- Publication Search
- Publication Details
Title
Drug development in the era of precision medicine
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 17, Issue 3, Pages 183-196
Publisher
Springer Nature
Online
2017-12-08
DOI
10.1038/nrd.2017.226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
- (2017) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Rare and low-frequency coding variants alter human adult height
- (2017) Eirini Marouli et al. NATURE
- Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
- (2017) David R Corey NATURE NEUROSCIENCE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers
- (2016) Dong Li et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development
- (2016) A. Yver ANNALS OF ONCOLOGY
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
- (2016) George E. Fragoulis et al. Annual Review of Medicine
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- A Precision Medicine Approach to Clinical Trials
- (2016) Rita Rubin JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- (2016) Derralynn A Hughes et al. JOURNAL OF MEDICAL GENETICS
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension
- (2016) Praveen Surendran et al. NATURE GENETICS
- Functional characterization of somatic mutations in cancer using network-based inference of protein activity
- (2016) Mariano J Alvarez et al. NATURE GENETICS
- The cancer vaccine resurgence
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
- (2016) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations
- (2016) Yukiko Ihara et al. PLoS One
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
- (2016) Jochen H. Weishaupt et al. TRENDS IN MOLECULAR MEDICINE
- Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency
- (2016) Patrick Maffucci et al. Frontiers in Immunology
- Quinidine in the treatment of KCNT1-positive epilepsies
- (2015) Mohamad A Mikati et al. ANNALS OF NEUROLOGY
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
- (2015) K. S. Tewari et al. CLINICAL CANCER RESEARCH
- Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies
- (2015) Ryan S. Dhindsa et al. Current Neurology and Neuroscience Reports
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- A roadmap for precision medicine in the epilepsies
- (2015) LANCET NEUROLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Personalized medicine: Time for one-person trials
- (2015) Nicholas J. Schork NATURE
- The impact of low-frequency and rare variants on lipid levels
- (2015) Ida Surakka et al. NATURE GENETICS
- Identification of a large set of rare complete human knockouts
- (2015) Patrick Sulem et al. NATURE GENETICS
- The support of human genetic evidence for approved drug indications
- (2015) Matthew R Nelson et al. NATURE GENETICS
- FTO Obesity Variant Circuitry and Adipocyte Browning in Humans
- (2015) Melina Claussnitzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiepileptic Drugs—A Review
- (2015) Ram Sankaraneni et al. PEDIATRIC ANNALS
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Rare Variants in NR2F2 Cause Congenital Heart Defects in Humans
- (2014) Saeed Al Turki et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Targeted treatment of migrating partial seizures of infancy with quinidine
- (2014) David Bearden et al. ANNALS OF NEUROLOGY
- KCNT1gain of function in 2 epilepsy phenotypes is reversed by quinidine
- (2014) Carol J. Milligan et al. ANNALS OF NEUROLOGY
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Obesity and FTO: Changing Focus at a Complex Locus
- (2014) Y.C. Loraine Tung et al. Cell Metabolism
- Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies
- (2014) LANCET NEUROLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Synaptic, transcriptional and chromatin genes disrupted in autism
- (2014) Silvia De Rubeis et al. NATURE
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Obesity-associated variants within FTO form long-range functional connections with IRX3
- (2014) Scott Smemo et al. NATURE
- The contribution of de novo coding mutations to autism spectrum disorder
- (2014) Ivan Iossifov et al. NATURE
- Amgen and Regeneron push for a genetic renaissance in drug discovery
- (2014) Michael Eisenstein NATURE BIOTECHNOLOGY
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- (2014) Carsten Linnemann et al. NATURE MEDICINE
- Lipid lowering with PCSK9 inhibitors
- (2014) Razvan T. Dadu et al. Nature Reviews Cardiology
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- GRIN2Amutation and early-onset epileptic encephalopathy: personalized therapy with memantine
- (2014) Tyler Mark Pierson et al. Annals of Clinical and Translational Neurology
- Dominant-negative effects ofKCNQ2mutations are associated with epileptic encephalopathy
- (2013) Gökce Orhan et al. ANNALS OF NEUROLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression
- (2013) Y.-C. Lu et al. JOURNAL OF IMMUNOLOGY
- De novo mutations in epileptic encephalopathies
- (2013) et al. NATURE
- De novo mutations in histone-modifying genes in congenital heart disease
- (2013) Samir Zaidi et al. NATURE
- Human genetics as a foundation for innovative drug development
- (2013) Alexander Kamb et al. NATURE BIOTECHNOLOGY
- Validating therapeutic targets through human genetics
- (2013) Robert M. Plenge et al. NATURE REVIEWS DRUG DISCOVERY
- The bigger picture of FTO—the first GWAS-identified obesity gene
- (2013) Ruth J. F. Loos et al. Nature Reviews Endocrinology
- Five Years of GWAS Discovery
- (2012) Peter M. Visscher et al. AMERICAN JOURNAL OF HUMAN GENETICS
- A Single-nucleotide Polymorphism in SCN9A May Decrease Postoperative Pain Sensitivity in the General Population
- (2012) Guangyou Duan et al. ANESTHESIOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Patterns of treatment response in newly diagnosed epilepsy
- (2012) M. J. Brodie et al. NEUROLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency
- (2011) R. E. Dickinson et al. BLOOD
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
- (2010) Kavya Rakhra et al. CANCER CELL
- Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
- (2010) F Stegmeier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci
- (2010) John D Reveille et al. NATURE GENETICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pain perception is altered by a nucleotide polymorphism in SCN9A
- (2010) F. Reimann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Common Genetic Variation and Human Traits
- (2009) David B. Goldstein NEW ENGLAND JOURNAL OF MEDICINE
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- A HapMap harvest of insights into the genetics of common disease
- (2008) Teri A. Manolio et al. JOURNAL OF CLINICAL INVESTIGATION
- Genome-wide association studies: progress and potential for drug discovery and development
- (2008) Stephen F. Kingsmore et al. NATURE REVIEWS DRUG DISCOVERY
- A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci
- (2008) Ying Liu et al. PLoS Genetics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More